IMARC Group, a leading market research company, has recently released a report titled “Gastroparesis Drugs Market Report by Disease Type (Diabetic Gastroparesis, Idiopathic Gastroparesis, Post-surgical Gastroparesis, and Others), Drug Class (Prokinetic Agents, Antiemetic Agents, Botulinum Toxin Injections), Distribution Channel (Hospitals and Clinics, Pharmacies, Online Stores), and Region 2024-2032”. The study provides a detailed analysis of the industry, including the global gastroparesis drugs market trends, size, share and growth forecast. The report also includes competitor and regional analysis and highlights the latest advancements in the market.
The global gastroparesis drugs market size reached US$ 6.5 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 9.5 Billion by 2032, exhibiting a growth rate (CAGR) of 4.3% during 2024-2032.
Request to Get the Sample Report: https://www.imarcgroup.com/gastroparesis-drugs-market/requestsample
Factors Affecting the Growth of the Gastroparesis Drugs Industry:
- Rising Prevalence of Diabetes:
The increasing prevalence of diabetes across the globe is creating a surge in demand for gastroparesis drugs. Gastroparesis is common among the diabetic population, particularly those with long-standing or poorly controlled diabetes, as high blood sugar levels can lead to damage to the vagus nerve, which controls the stomach muscles. This condition prevents the stomach from emptying properly and can severely affect quality of life. Apart from this, with the rising incidences of diabetes due to obesity, poor dietary habits, and sedentary lifestyles, there is a corresponding increase in the number of individuals suffering from diabetic gastroparesis, thereby strengthening the market growth.
- Advancements in Drug Development:
The gastroparesis drugs market is also benefiting from ongoing advancements in medical research and pharmacological innovation. The development of new prokinetic agents, which stimulate gastric emptying, thereby alleviating symptoms associated with gastroparesis and the introduction of antiemetic drugs that help reduce nausea and vomiting, improving individuals’ quality of life is contributing to market expansion. Pharmaceutical companies are investing in the research and development (R&D) of drugs that offer improved efficacy, fewer side effects, and better patient compliance compared to existing treatments. Besides this, the exploration of novel therapeutic targets and drug delivery systems is expanding the range of potential treatments available, providing impetus to the market growth.
- Increasing Awareness and Diagnosis Rates:
The escalating awareness among patients and healthcare providers about gastroparesis and its association with conditions such as diabetes and post-surgical complications has led to increased diagnosis rates. Educational campaigns by health organizations and patient advocacy groups have contributed to a broader understanding of the condition, prompting individuals experiencing symptoms to seek medical advice. Moreover, improvements in diagnostic methodologies, such as gastric emptying studies, endoscopy, and manometry, have facilitated more accurate and timely diagnosis of gastroparesis, thereby creating a positive outlook for market expansion.
Gastroparesis Drugs Market Report Segmentation:
By Disease Type:
- Diabetic Gastroparesis
- Idiopathic Gastroparesis
- Post-surgical Gastroparesis
- Others
Idiopathic gastroparesis represents the largest segment due to its high prevalence, as many patients with gastroparesis are diagnosed with the idiopathic form, where the cause is unknown.
By Drug Class:
- Prokinetic Agents
- Antiemetic Agents
- Botulinum Toxin Injections
Prokinetics dominate the market as they help treat gastroparesis effectively by enhancing gastric motility and providing symptomatic relief, making them a primary choice for healthcare providers.
By Distribution Channel:
- Hospitals and Clinics
- Pharmacies
- Online Stores
Hospitals and clinics account for the majority of the market shares because they are primary healthcare settings where diagnosis and treatment initiation for gastroparesis typically occur.
By Region:
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
North America leads the market due to its well-established healthcare infrastructure, high healthcare expenditure, and a relatively high prevalence of diabetes-related gastroparesis.
Global Gastroparesis Drugs Market Trends:
The growth of the gastroparesis drugs market is driven by the increasing geriatric population, who are more susceptible to gastrointestinal disorders like gastroparesis due to age-related physiological changes and an increased likelihood of surgeries that can affect gastric motility. In addition to this, the growing consumer interest and the availability of complementary and alternative medicine (CAM) options are contributing to the market expansion. Furthermore, the rise in the number of patients seeking fewer side effects and holistic treatment approaches has heightened the demand for new and innovative medications that align with CAM principles, propelling the market forward.
Top Companies Operated in Gastroparesis Drugs Industry:
- Abbott Laboratories
- Abbvie Inc.
- AstraZeneca Plc
- Bausch Health Companies Inc.
- Becton Dickinson and Company
- Boston Scientific Corporation
- Evoke Pharma
- Medtronic plc
- Neurogastrx Inc.
- Sanofi S.A.
- Takeda Pharmaceutical Company Limited
- Theravance Biopharma
Key Highlights of the Report:
- Market Performance (2018-2023)
- Market Outlook (2024-2032)
- Market Trends
- Market Drivers and Success Factors
- Impact of COVID-19
- Value Chain Analysis
- Comprehensive mapping of the competitive landscape
If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.
About Us:
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact US:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145
Content Source: https://writeupcafe.com/gastroparesis-drugs-market-size-share-demand-industry-growth-rate-forecast-analysis-2024-2032/
Comments
0 comment